Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth
You may also be interested in...
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
Co-promotion deal will assist Impax in ramping up its commercial team ahead of the launch of its own branded specialty drugs.
Biotechs that manage solid proof of concept in the challenging but potentially high-value area of opioid-induced constipation might find a receptive partnering audience in a variety of pharma quarters